JWK008
/ Genevector Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 25, 2024
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I
(clinicaltrials.gov)
- P1 | N=6 | Recruiting | Sponsor: West China Hospital
New P1 trial • Hurler Syndrome
1 to 1
Of
1
Go to page
1